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Abstract
This study aimed to identify the perception of public 
administrators from pharmaceutical services in 
subnational spheres, and of technical administrators 
from collegiate instances of the Brazilian National 
Health System on the impacts of the Farmácia 
Popular do Brasil Program (PFPB – Brazilian 
Popular Pharmacy Program), an exclusively federal 
initiative, in the administration of pharmaceutical 
services in primary health care (AFAB), of the 
responsibility of the three government levels and 
operationalized by the municipalities. Municipal, 
state and technical administrators from the 
National Council of Municipal Health Secretaries 
and from the National Council of Health Secretaries 
were interviewed. Content analysis considered the 
categories: (1) challenges and advances of AFAB 
and PFPB and (2) connections between AFAB and 
PFPB. There were different visions on the relations 
between them, either competing or complementing. 
The contrast between the growing investments 
in the PFPB and their stagnation in the AFAB, 
the overlapping of lists of medications, patient 
migration and the role of the PFPB as an access 
alternative, among others, were highlighted. The 
centralized implementation of the PFPB seems 
to have happened with poor articulation with 
subnational spheres of management, generating 
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distinct and conflicting interpretations about the 
program’s role and objectives for the municipalities, 
considering the decentralization guidelines of 
pharmaceutical services.
Keywords: Pharmaceutical Services; Primary 
Health Care; Health Management, Health Policy; 
Federalism.
Resumo
O trabalho teve como objetivo identificar a 
percepção de gestores públicos da assistência 
farmacêutica em esferas subnacionais e de 
gerentes técnicos de instâncias colegiadas do 
Sistema Único de Saúde sobre os reflexos do 
Programa Farmácia Popular do Brasil (PFPB), 
iniciativa exclusivamente federal, na gestão da 
assistência farmacêutica na atenção básica (Afab), 
de responsabilidade tripartite e operacionalizada 
pelos municípios. Entrevistaram-se gestores 
municipais, estaduais e gerentes técnicos do 
Conselho Nacional de Secretarias Municipais 
de Saúde e do Conselho Nacional de Secretários 
de Saúde. A análise do conteúdo considerou as 
categorias (1) desafios e avanços da Afab e do PFPB 
e (2) conexões entre a Afab e o PFPB. Houve visões 
divergentes sobre as relações entre Afab e PFPB, 
se concorrentes ou complementares. Ressaltou-se 
o contraste entre os crescentes investimentos no 
PFPB e sua estagnação na Afab, a sobreposição 
dos elencos, a migração de usuários e o papel do 
PFPB como alternativa de acesso, entre outros. 
A implementação centralizada do PFPB parece 
ter se dado com baixa articulação com as esferas 
subnacionais de gestão, gerando distintas e 
contraditórias interpretações sobre seu papel e 
objetivos para os municípios, considerando-se 
as diretrizes de descentralização da assistência 
farmacêutica.
Palavras-chave:  Assistência Farmacêutica; 
Atenção Primária à Saúde; Gestão em Saúde; 
Política de Saúde; Federalismo.
Introduction
Since the launch of the National Medicines Policy 
in 1998, institutional and normative changes began, 
aiming to harmonize pharmaceutical services (AF) 
and policies to the principles and guidelines of the 
Brazilian National Health System (SUS) – among them, 
decentralization. The new marks delegated most of the 
responsibility of providing medicines to outpatient 
treatment to the municipalities, which are responsible 
for listing, planning, making the procurement and 
distributing it in the context of primary health 
care (AB). The funding of pharmaceutical services 
in primary health care≈ (AFAB), in its turn, started 
being carried out in three parts, between the federal 
government, the states and municipalities (Kornis; 
Braga; Zaire, 2008).
However, several problems of public provision 
remain, making AFAB’s qualification an open 
agenda (Vieira, 2008). Some of the issues described 
in literature are: low availability of medicines, 
inadequate physical structure for storage and 
assistance, lack of qualified human resources, 
obstacles in procurement and logistical processes, 
insufficiency or delay of financial allocations and 
issues with suppliers, among others (Opas, 2005; 
Vieira, 2008).
Another relevant form of obtaining medicines 
for outpatient treatment in Brazil is through out-
of-pocket expenditure in community pharmacies 
and drugstores, a sector in expansion and driven 
by a market-oriented logic, remaining in many 
cases as the main source of access to medicines in 
Brazil (Pinto; Costa; Osorio-de-Castro, 2011; Silva; 
Caetano, 2016).
In 2004, Programa Farmácia Popular do Brasil 
(PFPB – Brazilian Popular Pharmacy Program) was 
started, implemented and managed exclusively by 
the federal government, in order to increase the 
access to medications through its availability at a low 
price, targeting mainly the low-income population 
that has private health insurances (Pinto; Costa; 
Osorio-de-Castro, 2011). The PFPB assists patients 
from public or private institutions in public or 
private facilities, and most of its medicines are listed 
in Relação Nacional de Medicamentos Essenciais 
(Rename – Brazilian National Relation of Essential 
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Medicines), coinciding with those offered in public 
facilities (Silva; Caetano, 2016).
During the evolution of the PFPB, its branch Aqui 
Tem Farmácia Popular (ATFP – There is a Popular 
Pharmacy Here)≈ – that is, medicines funded with 
copayment by the patient and the government in 
private pharmacies – has prevailed in a number of 
facilities and volume of directed resources when 
compared to the branch in public facilities. The 
partnership with drugstores has also been the 
main way of operation of the Saúde Não Tem Preço 
(SNTP – Health Has No Price) action – i.e. medications 
free of charge for high blood pressure, asthma and 
diabetes. The PFPB’s own network became residual 
over time (Mattos, 2015; Silva; Caetano, 2016).
Frenkel (2008) states that the creation of the 
PFPB represents a change of emphasis in state 
action, aiming at increasing access to medicines, 
regardless of the used tools. It represented, therefore, 
a change in the focus given so far –≈qualification of 
public services and exclusive use of this route to 
promote access. The program was among the four 
main priorities of the federal agenda in health during 
the 2000s (Machado; Baptista; Nogueira, 2011). 
Recent data on the growth of funding and amount of 
facilities in the program confirm this trend and show 
the effort of the federal government to implement the 
policy. From 2010 to 2015, the number of pharmacies 
registered in the program increased two and a half 
times, from 14,003 to 34,625.1
On the other hand, the funding of AFAB remains 
without adjustment of the federal financial 
counterpart since 2009, stagnated in R$ 5.10 (per 
capita value). In absolute terms, the resources 
allocated by the Ministry of Health (MS) were 
from more than R$ 970 million in 2010 to almost 
R$ 932 million in 2015¹, in current values, that is, a 
reduction of 5%. In the same period, the state and 
municipal counterparts went from R$ 1.86 to R$ 2.36.
Considering the fast expansion of PFPB and the 
difficulties in AFAB, it is expected that, locally, the 
dynamics of access has changed, bringing impacts 
and issues for public management in the subnational 
spheres. On the one hand, they are responsible for 
1  BRASIL. Ministério da Saúde. SAGE: Sala de Apoio à Gestão Estratégica. Available at: <http://sage.saude.gov.br/#>. Access on: 
Aug 1, 2016.
organizing and ensuring the provision of medicines 
within the AB. On the other hand, we can see the 
advance of a federal policy that takes place in private 
facilities that are not directly linked to the public 
health system. All these questions bring direct 
implications to the municipal administration.
Thus, the objective of this study is to identify 
the perception of public administrators from 
the pharmaceutical assistance in subnational 
spheres, and of technical administrators from 
collegiate instances of SUS on the reflections of 
the PFPB in AFAB and the practical implications 
of the coexistence between them to the municipal 
administration.
Method
This is a qualitative study based on semi-
structured interviews. We sought, as profile 
of the respondents, technical administrators 
from collegiate instances of the SUS and public 
administrators, preferably municipal health 
secretaries, representatives from municipalities with 
different population sizes and regions of the country. 
The inclusion criteria sought to value strategic 
decision-making and implementation positions in 
the SUS public management at the municipal level. 
The MS administrator was not interviewed since we 
intended to capture the vision of subnational spheres 
on the politics of the federal entity.
Thus, the first two interviews were conducted 
with technical administrators responsible for 
the Pharmaceutical Services area in Conselho 
Nacional de Secretarias Municipais de Saúde 
(Conasems – National Council of Municipal Health 
Secretaries) and in the Conselho Nacional de 
Secretários de Saúde (Conass – National Council 
of Health Secretaries). From them, an indication 
of municipal health secretaries and other public 
administrators was obtained. Among the interviewed 
secretaries, all occupied, in addition to their main 
function, some position in the Conasems, ranging 
from the presidency to specialized regional 
secretaries of the institution.
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In total, 12 public administrators were 
interviewed: technical administrators from Conass 
and Conasems, eight municipal health secretaries, 
one municipal AF administrator and one state AF 
administrator.
The questionnaire was tested previously, 
and contained four blocks of questions, namely: 
(1)  general situation of the AFAB in the municipalities, 
with main problems, advances and challenges; 
(2) MS’s responsibilities in guiding and organizing 
the health policies; (3) evaluation of PFPB’s impacts 
in municipalities and the role the program occupies 
within the AF policy; and (4)≈ possible relations 
between policies in different aspects.
Twelve interviews were performed by the main 
author between May and August 2014. Among the 
ten face-to-face interviews, one was performed on 
the road with this specific purpose (key informant), 
while the others occurred during the 30th National 
Congress of Health Departments. All interviews were 
recorded and transcribed.
Regarding the profile of the nine people linked 
to municipal administration, three were from the 
Southeast Region, two from the South, two from 
the Northeast, one from the Central-West and one 
from the North Region, representing seven different 
states. Regarding the population size, there were 
three administrators of each populational size 
group – small (up to 50 thousand inhabitants), 
medium (from 50 to 250 thousand inhabitants) and 
large (over 250 thousand inhabitants).
Regardless the authorization to disclose their 
names, we have decided to omit them. Aiming to 
indicate the position of the interviewees, citation 
marks designates the administrative position 
occupied and municipality population size (when 
applicable). Thus, administrators from collegiate 
bodies of SUS were classified as G-ICSUS (1 and 2), 
the state administrator as GE, the municipal ones 
as GM-P (1 to 3) in the case of small municipalities, 
GM-M (1 to 3) in case of medium-sized municipalities, 
and GM-G (1 to 3) for large-sized ones.
The content analysis (Bardin, 2011) of the speeches 
was synthetized in the following categories: challenges 
and advances of the AFAB and PFPB, and connections 
between them. Data treatment stages consisted in: 
transcription of the interviews, preliminary reading, 
in-depth reading, organization in thematic blocks, 
synthesis and selection, and interpretation. Two 
major thematic blocks were identified, from which 
the results’ presentation was structured.
All respondents expressed their consent with 
the use of the interviews by signing the Informed 
Consent Form. The project was approved by the 
Ethics Committee of the National School of Public 
Health Sérgio Arouca (process no. 626,060).
Results
Problems, progress and challenges in the provision 
of outpatient medicines funded by SUS
Among AFAB’s problems, there was unanimous 
reference to insufficient funding. The lack of value 
adjustment of the federal counterpart in the basic 
component of AF funding, the gap between the 
resources and the increased local demand driven 
by the expansion of the AB and AF policies, the 
rise of medicines prices, and the expansion of the 
list of drugs were selected. It has been repeatedly 
argued that the municipal level is overloaded 
and forced to allocate higher amounts than its 
counterpart to avoid shortages. I think the speed [of 
the expansion] of primary health care services hasn’t 
been accompanied by the AFAB funding. And then it 
creates a huge deficit for the municipality (GM-P1).
It was mentioned as aggravating factors: delay by 
the state level on transferring its counterparts and by 
the latter and federal level on delivering medicines 
on their responsibility, as well as the judicialization 
of the municipality for supplying medicines.
We want the MS to comply with its obligations. We 
have two months with delayed fund transfers. […] 
We endured almost all of 2013 without receiving 
contraceptives. (GM-P2)
You have a generic medicine that is the same thing. 
But the doctor says that it’s no good, the patient 
does not want it and the judge tells you to give that 
other product. (GM-P3)
Other citations points out the difficulties involved 
in medicines procurement, highlighting issues with 
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suppliers – such as the lack of companies interested 
in public procurement processes, the failure of the 
domestic market to meet the full demand, the delays 
in delivery and the non-compliance of contracts.
There is not enough in the market to supply the 
demand. The laboratories frequently say they don’t 
have the conditions, the productive and technological 
structure to meet such a demand. (GE)
Companies don’t want to sell to the public so they 
don’t go through the public procurement process, 
which fail, or nobody comes; those who enter don’t 
meet the requirements, don’t deliver, don’t quote; 
and the market is short on medicines for everyone. 
(G-ICSUS2)
“Bureaucracy” was related to the difficulty 
in complying with legislation related to public 
procurement, resulting in slowness of the processes, 
among other issues. Corruption was also a relevant 
issue, although less mentioned. Regarding logistics, 
in addition to the delays in delivery of medicines, 
problems were highlighted in organization, 
distribution infrastructure, inappropriate requests 
by units and the non-compliance of service by third 
party companies.
Sometimes it even causes shortages. It’s the whole 
procurement process, of prices benchmarking. 
(GM-M2)
It’s an area that is still linked to cartels, […] it’s linked 
to the practice of 10% of commission, it’s linked to 
the lack of public procurement process within the 
Secretariats. (GM-M1)
So if an unit […] didn’t make the correct request, and 
then it’s lacking. (GM-M3)
Human resources problems included insufficient 
professionals, low qualification and poor training, 
both in management as in care. Turnover, difficulty 
in hiring, and low wages were mentioned less 
frequently. There were no qualified people to perform 
AF in all units. We have a very capillary network to 
have people in all these places (GM-G1).
Regarding structure, the lack of conditions 
for storage, assistance and informatization were 
also highlighted. Less frequently, the overall low 
understanding of SUS administrators on the 
importance of structure was mentioned. On the 
other hand, some advances in these aspects were 
acknowledged. Today, I don’t have an effective control 
of dispensation, I don’t have anything computerized, 
I don’t even have internet in the units (GM-M3).
The interviewed considered that the MS has 
been supporting the municipalities to face the 
organizational and structural problems on AFAB 
management, especially from referred positive 
initiatives, such as the Programa de Qualificação 
da Assistência Farmacêutica no SUS (Qualifar-
SUS – SUS Pharmaceutical Services Qualification 
Program in SUS) and the Hórus system. These would 
have approached the MS to the municipalities and 
would represent an advance in the AF understanding 
beyond the logistical aspect.
Today you have the Hórus system, you get in a minute 
all the situation of the municipality. So, this is an 
advance. (GM-P2)
It moved from an understanding that was merely 
in terms of distribution, to take a first step in a 
more integrated discussion with municipalities. 
(G-ICSUS2)
However, there were questionings about the 
insufficiency of resources for greater effectiveness 
and extent of these actions and difficulties on its 
implementation.
From the state and municipal levels points 
of view, the solutions implemented or suggested 
by administrators to structure and organize the 
AFAB are diverse, being prior or simultaneous to 
federal initiatives. They quoted: greater internal 
organization, cooperation between municipalities 
and the more prominent action of the states. 
The State invested a lot, centralized pharmacies 
structure, created digital registration system. There 
are resources to contract pharmacists (GM-P3).
Specifically regarding the procurement of 
medicines, the intermunicipal consortium and state 
centralized purchases were considered relevant 
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experiences since they allowed obtaining lower 
prices, greater attendance from companies to public 
procurement process and greater supply stability. [The 
consortium] is the most well succeeded experience 
of medicines procurement, of planning, of regular 
delivery. Because you enlarge the scale, optimizing 
resources and ensuring distribution (GM-G2).
The situation that most interviewees thought 
to affect AFAB patients is the shortages on the 
supply, hindering access. Part of the population 
often have difficulty in accessing medications in 
SUS pharmacies (G-ICSUS1).
As irregular supply is a reality in AFAB, and 
the main positive point mentioned about the PFPB 
was that it works as access alternative in case of 
shortages. To the city manager, it’s the best thing in 
the world. If you don’t have it in the services, at least 
you have a place to send your patients to (GM-P2).
From an administrative perspective, it was 
questioned the low interaction between the federal 
and municipal levels within the PFPB, as well as the 
lack of accountability on results and of a clearly 
defined role of the program for the municipalities.
What results? We know the results we have. Now, 
what are the results of the Popular Pharmacy? 
(GM-P3)
It [MS] isn’t discussing it with the local administrator, 
they always think that we’re criticizing Popular 
Pharmacy. (GM-G3)
Regarding pharmaceutical care in AFAB, some 
municipalities with structured services made 
progress. However, the focus in logistical and 
managerial actions and the lack of specific efforts 
in this area are still limiting pharmaceutical care 
qualification. The weakness is the low quality of 
care. Actions are still directed to logistical aspects, 
[…] but there’s still a lot to do in pharmaceutical care, 
in follow-ups (GE).
Regarding PFPB, the lack of access to 
dispensing data in commercial pharmacies, the 
low concern with pharmaceutical services, the 
involvement of the private sector in the policy 
and its insufficient counterpart for the resources 
paid were mentioned.
The greatest disadvantage is that you don’t know 
the data about patients and medicines that are 
dispensed. (GM-P3)
The final objective of SUS, to take good care of the 
patient, may never be contemplated in the Popular 
Pharmacy. (GE)
Despite the difficulties, several public 
administrators consider there were important 
advances in the AFAB in recent years, enabling a 
significant improvement of this policy within the 
marks of decentralization. When talking about the 
general evaluation of PFPB, if positive or negative, 
answers were diverse. They highlighted the need 
for debates, revisions and adjustments in PFPB to 
correct imbalances.
Relations between pharmaceutical services in 
primary healthcare and Aqui Tem Farmácia Popular 
The first point mentioned was the contrast 
between the growing investments in PFPB on the one 
hand, and insufficient funding to AFAB on the other.
Today, most resources [from the] MS are spent 
far more with the PFPB than with primary care 
pharmacy. (GM-P1)
I’m funding the program more and not funding 
the policy. You are near [R$] 3 billion for the PFPB 
and [R$] 1.3 billion for the AFAB. That’s nearly 300 
items, and the PFPB does not reach 100. There’s a 
discomfort. (G-ICSUS2)
The different costs of the programs were 
shown as an aggravating factor, however, without 
unanimous understanding. Some stated that, in 
AFAB, government can get the lowest prices, while 
others had doubts.
The government pays for that medicine on PFPB ten 
times more than the it pays in public service. (GM-P3)
If you add up all the costs, what you spend in the 
Popular Pharmacy and in public services should be 
more or less equivalent. (GM-G1)
Saúde Soc. São Paulo, v.28, n.1, p.287-298, 2019  293 
When asked if there would be better results if 
PFPB’s resources were used in AFAB, there were 
divergences. Some stated that it would, some pondered 
the logistical costs, the planning and procurement 
difficulties in municipalities – or considered that it 
was not possible to evaluate the question.
We would have a much broader coverage, we would 
have quality in distribution and a higher satisfaction 
in treatment. (GM-M1)
It’s hard to know. Maybe, we might have the money, 
but might not make it [the medicine] available. 
(GM-G3)
Two possible consequences of this funding 
difference stood out: the symbolic delegitimation of the 
public sector and the admission of the AFAB weakness 
since shortages are common, unlike in PFPB.
Every time this medicine isn’t available in the public 
service, they try to get it at the private pharmacy, 
which discredits the public management. And then 
it’s the SUS management that is inefficient. So it’s 
bad for the SUS. (GM-M1)
If PFPB came […] to support, it means to say that 
there is a fragility of the AFAB. If this fragility didn’t 
exist, there wouldn’t be the program. (GM-P2)
Some administrators pointed that medicines sale 
on PFPB may be more commercially advantageous for 
producers and distributors. If there are restrictions 
on the market to meet the demand, it is possible 
that directing the supply to the PFPB contributes 
to the difficulties in municipalities procurements. 
However, there was disagreement on this hypothesis.
There can be interference, because the government 
pays a higher value there [in the PFPB]. For the 
distributor and manufacturer it’s better, as it has 
a more competitive price for their profitability. 
(G-ICSUS2)
I don’t see it [producers directing the supply to the 
PFPB]. I see that the small municipality has difficulty 
buying with competitive market prices. (GM-G2)
Overlapping part of the list of medicines of the 
two programs was mentioned, with differentiated 
perspectives. The first does not consider this an 
issue since segmenting the access would direct the 
demand among patients from public and private 
sectors. The second considered the overlapping 
contradictory, since it would be irrational that both 
models offer the same medicines.
Those that are patients from SUS, are treated there, 
they will get it in the public services. And those who 
are treated in the private sector should get it at the 
Popular Pharmacy. (GM-M3)
You’re creating a competition. The municipality 
has to buy and provide the same medicines that are 
available in Popular Pharmacy. (G-ICSUS)
The third and most frequent perspective pointed 
out that some municipalities would no longer offer 
the common medicines of PFPB list to use the saved 
funds for purchasing other medicines.
There are several [municipal] administrators today 
that no longer purchase those medicines that are 
available in Popular Pharmacy. (GM-M2)
This is happening [municipalities stop buying 
medicines from the PFPB]. But in a strategic way? 
No. It’s an adequation due to insufficient funds. 
(G-ICSUS2)
Concerning the preference of the population 
for one of the two sources, most stated that the 
population prefers to obtain their medications 
directly in the AFAB. The population that goes to the 
public service, if they have a guarantee that the drug 
is there, they do not go to PFPB (GM-P1).
However, situations were mentioned in which 
specific segments may prefer the PFPB, such as 
retirees, health insurance clients and the high-
schooling population – or even cases in which the 
geographical accessibility and the working hours 
of the participating pharmacies are better than the 
public services.
Regarding care, qualitative differences were 
highlighted between the type of assistance provided 
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in each of the policies, especially the vision that 
there is a greater concern with care, integrality and 
linkage in AFAB, while the PFPB focus is in providing 
the medicines.
We think this interferes within the strategy that we 
want, which is the integration of the patient with his 
neighborhood, and that connected to primary care 
facilities. (GM-M1)
They distribute the medicines. It’s not even a 
dispensation. (GM-M2)
Discussion 
This study aimed to assess from the perspective 
of SUS administrators the reflexes and relations 
arising from the coexistence of different public 
policies to provide outpatient medicines: AFAB 
and PFPB. We chose to analyze the point of view 
of administrators from subnational instances of 
SUS instead of the federal vision, since those are 
designers and managers of the policy.
A series of AFAB problems were signaled in 
most different aspects of public management, with 
results both in the structure and organization of the 
system and in the care given to patients. There was 
no consensus on the type of relation between PFPB 
and AFAB, whether of competition or cooperation. 
Responses showed several nuances, according to the 
different aspects approached and often revealing 
contradictory speeches.
Concerning funding, two elements stand out. First, 
the evolution of the resources destined by the MS 
to PFPB and to AFAB. When compared, the growing 
investments in the first and decreasing in the second 
were evidenced. While PFPB, with a more restrict list 
of medicines, had an increase of 1055% in their budget 
from 2010 to 2015, AFAB, with a broader list, have 
had its per capita funding frozen since 2009 (Silva; 
Caetano, 2016). Additionally, the lack of resources for 
AFAB has overloaded the municipalities because both 
the demand and the medicine’s price have increased 
(Machado et al., 2014).
The second element refers to the costs of PFPB 
and AFAB. Two studies, which considered logistics, 
structure, human resources and depreciation costs, 
concluded that PFPB’s costs are from 150% (Carraro, 
2014) to 255% (Silva; Caetano, 2016) higher than 
AFAB’s. It is possible that, in smaller municipalities, 
with a small scale of procurement and/or with a less 
structured AF, the values spent on public purchases 
are equivalent or superior to the PFPB. However, no 
evidences were found to support this hypothesis.
Regarding medicines public procurement, 
aspects such as insufficient resources, corruption 
and lack of accountability, lack of technical bodies 
to deal with the norms related to the procurement 
processes, and low interest of suppliers are 
supported by the literature (Vieira, 2008). The lack of 
interest of manufacturers in procurement processes 
was partially considered by the Conass (2014) in a 
technical note.
No evidences were found regarding the 
insufficiency of the pharmaceutical productive 
structure to meet simultaneously the demands 
of municipalities and the retail market – neither 
regarding a production directing to ATFP’s demand. 
On this hypothesis, possible explanations would be 
the greater sales return when negotiating with the 
retail market, given the higher prices practiced, the 
magnitude and stability of demand, the existence 
of previously established distribution channels 
with pharmacies, and the lower operational cost for 
suppliers, allowing them to escape bureaucracy and 
bidding requirements. These are important hypothesis 
that deserve to be investigated in future studies.
Another consequence arising from the under-
funding and overlapping of medicines would be 
the interruption of the supply in AFAB of those 
medicines which are also included in PFPB. Thus, 
administrators could use the scarce resources of 
AFAB to purchase other medicines previously not 
included or to ensure the full supply of a smaller 
list of medicines, while the population would 
obtain those overlapped medications exclusively 
in PFPB. Despite the need for studies to evaluate 
this situation, these cases are worrisome since, in 
practice, represent the replacement of AFAB by PFPB 
for certain drugs.
In other management related activities, such 
as storage, stock control and purchases planning, 
the speeches of administrators regarding AFAB 
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are supported by scientific literature (Opas, 2005; 
Vieira, 2008). The same happens when it comes to 
infrastructure issues, such as the inadequacy and 
insufficiency of spaces of assistance and storage, the 
lack of air conditioning and the low internet access 
(Mendes et al., 2014), although there may be local or 
regional successful cases. The MS initiatives to deal 
with these issues, notably the Hórus system (Costas; 
Nascimento Júnior, 2012) and the Qualifar-SUS 
program (Brasil, 2012), were considered important, 
although insufficient or little comprehensive, even 
if there are generally not enough funds in a scenario 
where supply is considered more important than care. 
Reports point out that well succeeded solutions 
for logistical and structural aspects are related to 
the protagonism of the state level and to a greater 
intermunicipal cooperation. Concerning medicines 
procurement, studies showed that the consortium 
system actually generates savings for the participant 
entities and greater supply stability (Amaral; Blatt, 
2011; Ferraes; Cordoni Júnior, 2007). The role of the 
states seems to have been decisive in some successful 
cases of organizing and qualifying AFAB (Faleiros; 
Silva, 2014; Ferraes; Cordoni Júnior, 2007).
In addition to problems on AFAB, the arguments 
that support the recognition of the PFPB as an access 
alternative by the administrators are, on the one 
hand, the shortage in the public services and, on the 
other, the ensured availability in PFPB.
Shortage in AFAB is not a new situation (Vieira, 
2008). A nationwide survey applied in primary 
care facilities identified an availability of key-
medicines of 56.1% (Mendes et al., 2014). In the 
same direction, a national household survey shows 
that the availability of medications for chronic 
diseases as being of 45.2%, 67.4% and 88.5%, in the 
SUS, PFPB and in private pharmacies, respectively 
(Oliveira et al., 2016). The high availability of 
medications has been reported in PFPB, both in 
its public pharmacies (Bonotto; Colet, 2013; Pinto 
et al., 2010) and in ATFP (Pinto et al., 2010), as 
well as with community pharmacies (Opas, 2005). 
Nevertheless, even in the case of hypertension and 
diabetes, in which medicines are free in SNTP, about 
18% of the interviewed claimed to have obtained 
their medicines from it, and 60.5% of them obtained 
from SUS (Brasil, 2016).
On the different perspectives regarding AFAB 
and PFPB utilization dynamic, different studies have 
found out that around half the prescriptions in PFPB 
are originated in public services (Bonotto; Colet, 2013; 
Carraro, 2014; Pinto; Costa; Osorio-de-Castro, 2011). 
This fact reinforces the thesis of PFPB eventual use 
of PFPB in SUS shortage situations. Thereby, the 
stock-outs in AFAB and the ensured access on PFPB 
are characteristics that reinforce themselves and act 
inducing the migration from a source of access to the 
other, eventually or definitively. It is worth mentioning 
an administrator’s recurrent speech: when medicines 
are available in AFAB, patients prefer to obtain it where 
they are treated – and PFPB helps municipalities as it 
protects the patients in case of shortage.
The administrators’ speech pointed out the need 
to broaden the discussion around this theme in order 
to clarify and define the role of each policy and of 
each government level. The distinct interpretations 
regarding the PFPB’s role may be related not only 
to its practical implications but also to its top down 
implementation, without dialogue with subnational 
spheres.
Arretche (2004) argues that the participation of 
states and municipalities in health policy formulation 
process, realized through representatives councils, 
has worked as counterweight to the authority 
concentration in federal level, removing from the MS 
the possibility to decide individually SUS framework 
and rules. However, this is not observed in the case 
of PFPB, a policy designed and implemented at 
the federal level. According to the interviewees, 
decisions and discussions around directions of the 
program have not passed through these councils 
and interagency commissions. In addition, PFPB 
does not count with representatives of subnational 
spheres on its centralized management model, and 
the federal government does not provide normative 
guidelines or formal instructions to the other levels 
on the implications of the program to the local 
dynamics of medicine supply.
In this case, it is entirely up to the municipalities 
to interpret and act on the new reality of coexistence 
between the policies, which goes in the opposite 
direction of a broader movement to strengthen 
inter-federative instances and make agreements 
on responsibilities.
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In practice and in terms of management and of 
service utilization, what seems to occur is that the 
rise of PFPB redefines the role of AFAB indirectly, 
once the space occupied by the latter policy is 
modified when it starts coexisting with the first one. 
Thus, there is no coordination between the actions.
Guimarães and Giovanella (2004) indicate 
that, despite the importance of the cooperation 
between administrative levels as a key factor in 
the implementation of health policies in federative 
countries, competitive relations have prevailed in 
Brazil. In the case in question, on the one hand, PFPB 
is perceived as a top down action distant from the 
cooperation between federated levels. In contrast, 
initiatives such as the creation of Hórus system 
and the Qualifar-SUS program go in the opposite 
direction, as highlighted by the administrators. This 
indicates that MS has different attitudes towards 
other AF management levels, depending on the 
action or policy in question.
Still on the MS performance, Fonseca and 
Costa (2015) analyzed high-cost pharmaceutical 
services and concluded that there was choice on 
re-centralizing activities at federal level, aiming to 
stimulate the health industrial and economic complex 
development. It has been argued (Pinto; Costa; Osorio-
de-Castro, 2011) that PFPB has been used for the same 
purpose, which would partially explain its top down 
administration and its strength within the federal 
agenda. An additional function of centralization in 
the program would be the possibility of using the 
policy as a Federal Executive Government brand 
(Pinto; Costa; Osorio-de-Castro, 2011)
The use of interviews and the exploratory 
character of this study proved to be adequate, since 
it allowed to evidence problems already known and 
to identify new hypothesis. However, the nature 
and scope of the study limits its external validity, 
even though the attempt to address administrators 
from municipalities of different sizes has sought 
to incorporate different perspectives on questions 
generated by PFPB at this management level.
Final considerations
The interviewed administrators’ different 
interpretations on the role and objectives of PFPB 
were evidenced, probably reflecting the lack of clear 
directions and scarce dialogue between the federal 
level and the subnational spheres during policy 
implementation.
Questions raised on the relations between the 
two policies are a direct consequence of a context in 
which - on the one hand – the public provision policy, 
designed in the framework of decentralization with 
shared responsibilities between federative levels, 
suffers from chronic problems despite important 
advances. And – on the other hand – another policy 
emerges with similar goals (PFPB), led exclusively 
by the federal government, which, unlike the 
AFAB’s case, has been investing greater efforts and 
resources for implementation.
Overall, in the speeches competition was 
associated to a greater directing of federal resources 
to the PFPB in contrast to the lack of adjustment 
of AF’s budget, to a possible effect in the market – 
which would hinder purchasing, to the overlapping of 
medicines list which would lead some administrators 
to choose not to offer PFPB medicines in AFAB, to 
a possible migration of patients from one policy 
to another, and to the differences in offered care. 
The policies were considered complementary by 
the administrators in cases in which AF is not 
fully structured, with PFPB working as an access 
alternative in case of stock-out in the public primary 
care facilities, or when the program assists different 
patients from AFAB.
The notion of “complementarity” should 
be questioned when applied to the relations 
between AFAB and PFPB. The word evokes the 
connotation of a virtuous relation between policies, 
as if their characteristics reinforce and potentialize 
themselves. However, many of the consequences 
described in this study do not seem to go in that 
direction. Some situations seem to happen not due 
to a complementary design among the policies, but 
originated from AFAB failures.
Thus, it is possible to state the coexistence 
between the two policies has redefined the role of 
AFAB, even if indirectly. The extent of its fragilities, 
added to the vigorous implementation of the PFPB, 
have consequences in the use at local level and 
influence the decisions of municipal administrators 
in conducing the local AF policy.
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Several statements of the interviewed 
administrators’ are supported by the literature, 
whereas others raise important hypotheses of topics 
to be investigated.
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